Congress finds the fees will be dedicated to monograph drug activities
What the document says“Congress finds that the fees authorized by the amendments made in this title will be dedicated to over-the-counter (OTC) monograph drug activities, as set forth in the goals identified for purposes of part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j-71 et seq.)”
The finding ties the fees to a set of performance goals agreed between the agency and industry, set out in letters from the Secretary of Health and Human Services to the chairmen of the Senate health committee and the House Energy and Commerce Committee.
What the document actually says“Congress finds that the fees authorized by the amendments made in this title will be dedicated to over-the-counter (OTC) monograph drug activities, as set forth in the goals identified for purposes of part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j-71 et seq.)”
Congress says the fees will pay for work on drugs sold without a prescription.
The goals for that work are written in letters, not in the law. The letters were printed in the record of Congress.
No action is recorded against this proposal. That is not evidence that none has been taken, and nobody has yet read it against the record. See what the tracker does not yet cover.